Over the past decade, oncology has begun to leverage a rapidly maturing effort to target the KRAS protein in KRAS-altered cancers. This has led to the introduction of targeted therapies with the potential to offer unprecedented benefit to patients. Still, these agents differ greatly in their mechanisms of action, relevant alterations, and adverse event profiles. In this module, expert faculty discuss the use of RAS/MAPK inhibitors in the setting of RAS-altered gynecologic malignancies. In particular, the speakers will address patient selection, expectations regarding efficacy, and the management of adverse events associated with novel targeted therapies for these patients.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Pricing
100% of listed courses are free
272 of 272 courses listed here are free.
Collected from the provider’s public pages · source
Specialties served/covered
- Allergy & Clinical Immunology
- Anatomic & Clinical Pathology
- Cardiovascular Disease
- Communication & Shared Decision-Making
- Dermatology
- Endocrinology, Diabetes & Metabolism
- Evidence-Based Medicine & Research
- Family Medicine
- Gastroenterology
- Gastrointestinal Surgery
- General & Adult Psychiatry
- General Internal Medicine
- General Pediatrics
- Geriatric Medicine
- Gynecologic Oncology
- Head & Neck Surgery
- Health Equity & Inclusion
- Hematology
- Infectious Disease
- Medical Oncology
- Metabolic & Bariatric Surgery
- Mood & Anxiety Disorders
- Nephrology
- Neurology
- Neuromuscular Medicine
- Neuroradiology
- Neurosurgery
- Nuclear Medicine
- Ophthalmology
- Pediatric Hematology-Oncology
- Psychotic Disorders
- Pulmonary Disease
- Radiation Oncology
- Rheumatology
- Surgical Oncology
- Urological Oncology
- Cardio-Vascular
- Cross-Specialty
- ENT & Head Neck
- GI & Liver
- Infectious Disease
- Internal Medicine
- Medical Subspecialties
- Neurology
- Oncology & Hematology
- Pathology & Lab
- Pediatrics
- Primary care
- Psychiatry
- Radiology
- Surgery
- Urology
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Online course / module
- Credit · Up to 0.5 credits
- Commercial Support
-
ReleasedAug 31, 2026
-
Last day to claim creditSep 1, 2027 11 months left
-
Answers in CME Inc. (AiCME) RAS(ON) Inhibition: On the Path to Overcoming Therapeutic Resistance and Targeting More Variants in KRAS-Mutated NSCLC
-
Clinical Care Options, LLC (dba Decera Clinical Education) Conference to Clinic: A Test-Your-Knowledge Challenge of Emerging Next-Generation KRAS G12C-Targeted Therapies in NSCLC
-
touchIME, USF Health RAS mutations and personalized cancer care: Targeting the Future
